Structural Flexibility of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitor: 9-Cl TIBO as Explained by Potential Energy Surface and 13C and 1H NMR Calculations, Based on ab initio and Density Functional Study

The conformational analysis of the HIV-1 reverse transcriptase inhibitor, (+)-(s)-4,5,6,7-tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)imidazol[4,5,1-jk][1,4]benzodiazepin-2(1H)-thione or 9-Cl TIBO, has been investigated using high level of calculations, ab initio, and DFT theory. The potential energy surface as the function of two important rotatable dihedral angles of the 9-Cl TIBO side chain was generated by the Hartree-Fock method at the 3-21G basis set. Eight pronounced local minima were found to exist within an energy difference of less than 10 kJ/mol. The energy barriers between the different local minima are lower than 15 kJ/mol. A second derivative (frequency) analysis showed that all conformers are stable at this level of theory. These structures were used as starting points for full geometry optimizations at the HF/6-31G and B3LYP/6-31G levels of theory to obtain the absolute geometries and structural information. The comparisons of calculated conformers with the bound conformer in the X-ray structure were sequentially considered. Additionally, to obtain some structural information and to correlate between calculated structures and the structure in solution, NMR chemical shift calculations were also performed on all eight local minimum structures at B3LYP/6-311++G level, using the GIAO approach. The calculated (1)H NMR and (13)C NMR chemical shifts for the lowest energetic conformer give the greatest correspondence with the experimental results.

[1]  P. Wolschann,et al.  Molecular Calculations on the Conformation of the HIV-1 Reverse Transcriptase Inhibitor (+)-(S)-4,5,6,7-Tetrahydro-8-chloro-5-methyl-6-(3-methyl-2-butenyl)-imidazo[4,5,1-jk][1,4] benzodiazepine-2(1H)-thione (8-Chloro-TIBO) , 2001 .

[2]  Henri Moereels,et al.  Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors , 1995, Nature Structural Biology.

[3]  Jianping Ding,et al.  Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies. , 1996, Drug design and discovery.

[4]  S. Galembeck,et al.  Conformational preferences of non-nucleoside HIV-1 reverse transcriptase inhibitors , 2001 .

[5]  P. Janssen,et al.  Differential antiviral activity of two TIBO derivatives against the human immunodeficiency and murine leukemia viruses alone and in combination with other anti-HIV agents. , 1993, AIDS research and human retroviruses.

[6]  Supa Hannongbua,et al.  Conformational analysis of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, based on quantum mechanical calculations , 2001, J. Comput. Aided Mol. Des..

[7]  Erik De Clercq,et al.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives , 1990, Nature.

[8]  A. D. Clark,et al.  Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. , 1996, Journal of molecular biology.

[9]  G. Trainor,et al.  Synthesis and evaluation of analogs of Efavirenz (SUSTIVATM) as HIV-1 reverse transcriptase inhibitors , 1999 .

[10]  C. Alsenoy,et al.  Ab initio study of tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione (TIBO) derivatives R79882 and R82913 , 1995 .

[11]  P. Wolschann,et al.  Conformational Study of the HIV-1 Reverse Transcriptase Inhibitor 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) , 1999, Biological chemistry.

[12]  J. Tomasi,et al.  The IEF version of the PCM solvation method: an overview of a new method addressed to study molecular solutes at the QM ab initio level , 1999 .

[13]  Yvonne Jones,et al.  Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors , 1995, Nature Structural Biology.

[14]  W. Schäfer,et al.  Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations. , 1993, Journal of medicinal chemistry.

[15]  Jianping Ding,et al.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. , 1994, Journal of molecular biology.

[16]  E. Clercq,et al.  Antiviral therapy for human immunodeficiency virus infections. , 1995 .

[17]  S. Sarafianos,et al.  Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Stuart,et al.  The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. , 1995, Structure.

[19]  Erik De Clercq,et al.  The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection , 1998 .

[20]  J. Adams,et al.  Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. , 1990, Science.

[21]  P. Mui,et al.  Crystal structure of nevirapine, a non-nucleoside inhibitor of HIV-1 reverse transcriptase, and computational alignment with a structurally diverse inhibitor. , 1992, Journal of medicinal chemistry.

[22]  G. Leo,et al.  Conformational analysis of the reverse transcriptase inhibitor (+)-(S)-4,5,6,7-tetrahydroimidazo-9-chloro-5-methyl-6-(3-methyl-2-butenyl) imidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thione (TIBO; R82913) , 1993 .

[23]  Trygve Helgaker,et al.  Ab Initio Methods for the Calculation of NMR Shielding and Indirect Spin-Spin Coupling Constants , 1999 .

[24]  E. De Clercq,et al.  The HIV‐1 Reverse Transcription (RT) Process as Target for RT Inhibitors , 2000, Medicinal research reviews.

[25]  E. De Clercq,et al.  New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs , 1994, Antimicrobial Agents and Chemotherapy.

[26]  E. Arnold,et al.  Major subdomain rearrangement in HIV‐1 reverse transcriptase simulated by molecular dynamics , 1999, Proteins.

[27]  Peter Pulay,et al.  Efficient implementation of the gauge-independent atomic orbital method for NMR chemical shift calculations , 1990 .

[28]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..